Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 17/20 | 0.85 |
| ▸ | CPT1B | Q92523 | 16/20 | 0.68 |
| ▸ | CPT2 | P23786 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844841 | 0.92 | CPT1A (0.84) | CPT1ACPT1BCPT2 | |
| SCHEMBL2903312 | 0.92 | CPT1A (1.00) | CPT1ACPT1BCPT2 | |
| SCHEMBL3844839 | 0.90 | CPT1A (0.96) | CPT1ACPT1BCPT2 | |
| SCHEMBL2898313 | 0.90 | CPT1A (0.84) | CPT1ACPT1BCPT2ALDH1A1 | |
| SCHEMBL753538 | 0.89 | CPT1A (0.86) | CPT1ACPT1BCPT2 | |
| SCHEMBL750332 | 0.87 | CPT1A (0.86) | CPT1ACPT1BCPT2ALDH1A1 | |
| SCHEMBL2904429 | 0.86 | CPT1A (0.85) | CPT1ACPT1BCPT2ALDH1A1 | |
| SCHEMBL752639 | 0.85 | CPT1A (0.84) | CPT1ACPT1BCPT2ALDH1A1LMNA | |
| SCHEMBL753138 | 0.85 | CPT1A (0.85) | CPT1ACPT1BCPT2 | |
| SCHEMBL751604 | 0.85 | CPT1A (0.85) | CPT1ACPT1BCPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799933-B2 | Sulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2097373-B1 | SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| EP-2097373-A1 | SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) | F. Hoffmann-Roche AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-20080153805-A1 | SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008074692-A1 | SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153805-A1 | SULFONAMIDE DERIVATIVES | CPT1A, SULT2A1, SULT1A1 | CPT1A 1/4885CPT1B 5/4885CPT2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.